688131.SH
Shanghai Haoyuan Chemexpress Co. Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 83.61
+7.45%Oct 29, 2026, 10:01 UTC
Hao Yuan Chemexpress reported first-three-quarter 2026 revenue of 2.646 billion yuan, up 28.52% year over year, and attributable net profit of 309 million yuan, up 30.49%.
Source:Oct 29, 2026, 10:01 UTC
Hao Yuan Chemexpress reported third-quarter 2026 revenue of 998 million yuan, up 33.44% year over year, and attributable net profit of 138 million yuan, up 62.10%.
Source:Sep 11, 2026, 08:32 UTC
Shanghai Chenxiao, Shanghai Chenmai and Shanghai Chenxi, pre-IPO employee shareholding platforms of Haoyuan Pharma, plan to reduce their combined stake in the company by no more than 2.34% via centralized bidding between September 17 and December 16, 2026.
Source:Aug 26, 2026, 10:37 UTC
Haoyuan Pharmaceutical proposed a cash dividend of 0.90 yuan per 10 shares for the first half of 2026, totaling 19.1911 million yuan, representing 11.21% of net profit attributable to shareholders.
Source:Aug 16, 2026, 13:57 UTC
Haoyuan Pharmaceutical disclosed that as of the end of Q1 2026, its small-molecule order backlog was 860 million yuan, growing quarter-over-quarter for six consecutive quarters, and ADC order backlog exceeded 100 million yuan.